Maravai LifeSciences Q1 2024 Adj EPS $(0.02) Beats $(0.03) Estimate, Sales $64.179M Beat $60.548M Estimate
Portfolio Pulse from Benzinga Newsdesk
Maravai LifeSciences (NASDAQ:MRVI) reported Q1 2024 adjusted EPS of $(0.02), beating estimates by 33.33% but marking a 166.67% decrease from last year. Sales reached $64.179M, exceeding estimates by 6% but showing an 18.79% decrease from the previous year.
May 08, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Maravai LifeSciences reported a Q1 2024 adjusted EPS of $(0.02), surpassing estimates, and sales of $64.179M, also beating expectations but showing a significant year-over-year decrease.
While Maravai LifeSciences beat both EPS and sales estimates for Q1 2024, the significant year-over-year decreases in earnings and sales may temper investor enthusiasm. The positive beat on estimates could provide some short-term positive sentiment, but the overall decline in performance compared to the previous year might limit upside potential.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100